Takeda reported head-to-head Phase 3 data showing its AI-designed oral psoriasis drug, zasocitinib, achieved total skin clearance in more than 35% of patients at week 16. In the company’s comparisons, that response rate exceeded Bristol Myers Squibb’s Sotyktu by a factor of more than 2.5, with benefits visible by week 8. The trial also showed stronger secondary endpoints, including PASI 90 response. Takeda said the results support what it called “de-risk[ing]” a potential regulatory path for the once-daily pill, with an FDA filing expected in the coming months. Zasocitinib was acquired from Nimbus Therapeutics in December for $4 billion. The mechanism centers on targeting TYK2 while maintaining IL-23 inhibition for about 24 hours, which Takeda argues supports rapid and durable clearance. For psoriasis developers, the data directly changes the efficacy benchmark for oral TYK2-class approaches, potentially tightening competitive expectations ahead of regulatory review.